ArticleCanadian journal of psychiatry. Revue canadienne de psychiatrie2015
Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia.
Article in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Antipsychotic treatment adherence and motor vehicle crash among drivers with schizophrenia: a case-crossover study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Leveraging Model Master Files for Long-Acting Injectables.Pharmaceutical research · 2025Article
- Effect of long-acting injectable antipsychotics on treatment adherence and healthcare utilization in Chinese patients with schizophrenia: a mirror-image study.Therapeutic advances in psychopharmacology · 2025Article
- Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: Summary of workshop.CPT: pharmacometrics & systems pharmacology · 2023Review
- Review
- Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine.NPJ schizophrenia · 2020Article
- Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study.Clinical drug investigation · 2020Article
- Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry.Therapeutic advances in psychopharmacology · 2020Article
- [Long-acting antipsychotics: The QAAPAPLE algorithm review].Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2019Article
- Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting.Neuropsychiatric disease and treatment · 2019Article
- Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec.Therapeutic advances in psychopharmacology · 2018Article
- A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder.Therapeutics and clinical risk management · 2016Review
- The 10th Anniversary of the Eli Lilly Chair of Schizophrenia from the University of Montreal.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo better understand the treatment patterns, persistence and compliance, resource use, and associated costs, of long-acting injectable antipsychotics (LAI-AP), using the Régie de l'assurance maladie du Québec database.
methodPatients with schizophrenia or schizoaffective disorder who were incident users of an LAI-AP prescribed between January 1, 2008, and March 31, 2012, were selected. Concomitant use of oral APs and treatment persistence and compliance with LAI-AP were analyzed. Patients were considered compliant if they had a medication possession ratio (MPR) of at least 0.80. Health care resource use (HCRU) and associated costs were analyzed during the year before and after LAI-AP initiation.
resultsA total of 1992 patients met the inclusion criteria. The average persistence with LAI-AP was 217.2 days (SD 144.2). The mean MPR with LAI-AP during the postinitiation year was 0.58 (SD 0.35), with 37.5% of patients being compliant. In the preinitiation year, 29.0% of patients were compliant with previous oral AP. In the pre- and postinitiation periods, 1484 and 958 patients had at least 1 hospitalization, and hospitalized days were reduced by one-half (P<0.001). Cost of HCRU, including medication, was significantly decreased from $24,382 (SD $27,234) to $13,090 (SD $16,987), respectively, in the pre- and postinitiation years (P<0.001).
conclusionsThe initiation of an LAI-AP improved treatment compliance, compared with previous oral APs, resulted in significantly lower HCRU and costs. The primary drivers were the reduction in the occurrence and days of hospitalizations.
Indexed as
Identifiers
25886679PMC4418621W2410204026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.